Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors
摘要:
A novel series of competitive, reversible cathepsin S (Cats) inhibitors was discovered and optimized. The 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety was found to be an effective replacement for the 4-arylpiperazin-1-yl group found in our earlier series of Cats inhibitors. This replacement imparted improved PK properties as well as decreased off-target activity. Optimization of the ketobenzimidazole moiety led to the discovery of the lead compound JNJ 10329670, which represents a novel class of selective, noncovalent, reversible, and orally bioavailable inhibitors of cathepsin S. (c) 2005 Elsevier Ltd. All rights reserved.
DOI:
10.1016/j.bmcl.2005.01.045
作为产物:
描述:
N-乙酰基-4-哌啶酮 、 哌啶 、 对甲苯磺酸 、 4-溴苯甲酰氯 、 、 盐酸 、 肼 在
二氯甲烷 、 碳酸氢钠 、 水 、 Brine 、 Sodium sulfate-III 、 甲醇 作用下,
以
二氯甲烷 、 苯 为溶剂,
反应 55.5h,
以to give 52 g (50%) of the title compound which的产率得到1-[3-(4-bromo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone
Method for treating allergies using substituted pyrazoles
申请人:Butler R. Christopher
公开号:US20050101587A9
公开(公告)日:2005-05-12
A method for treating an allergic condition, including an atopic allergic condition, using substituted pyrazoles.
使用取代吡唑烷治疗过敏症状的方法,包括特应性过敏症状。
Substituted pyrazoles and methods of treatment with substituted pyrazoles
申请人:Butler R. Christopher
公开号:US20070117785A1
公开(公告)日:2007-05-24
Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases or allergic conditions, including atopic allergic conditions, mediated by cathepsin S are described.